AllDocs -> cancers

Letter to the editor of J Cellular Oncology Towards a single cell cancer diagnosis . Multimodal and Monocellular Measurements of Markers and Morphology (5M) A. Böcking 1 , J. Stockhausen 2 , D. Meyer-Ebrecht 2 Dear Professor Reith, We would like to draw the attention of the readers of the Analytical Cellular Pathology journal towards recent developments in diagnostic cytopathology, which deserve interest by pathologists, cytologists, biologists, clinicians, engineers and public health economists: The increasing possibilities to diagnose different malignant tumors in early stages painlessly and without bloody biopsies or surgery on a comparably low number of cells. 1. Aims of diagnostic cytopathology The aims of diagnostic cytopathology mainly are - to early identify either so far unknown (pre-)malignant ...

Joint Classifier and Feature Optimization for Cancer Diagnosis Using Gene Expression Data Balaji Krishnapuram Dept. of Elec. Engineering Duke University Durham, NC 27708 balaji@ee.duke.edu Lawrence Carin Dept. of Elec. Engineering Duke University Durham, NC 27708 lcarin@ee.duke.edu Alexander J. Hartemink Dept. of Computer Science Duke University Durham, NC 27708 amink@cs.duke.edu ABSTRACT Recent research has demonstrated quite convincingly that accurate cancer diagnosis can be achieved by constructing classifiers that are designed to compare the gene expression profile of a tissue of unknown cancer status to a database of stored expression profiles from tissues of known cancer sta- tus. This paper introduces the JCFO, a novel algorithm that uses a sparse Bayesian approach to jointly identify both the optimal ...

Neutron-Based Imaging May Lead to Earlier Breast Cancer Diagnosis Carey Floyd ( carey.floyd@duke.edu ) 12 , C Howell 2 , A Kapadia 2 , B Harrawood 1 , J Xia 2 , G Tourassi 1 , (1)Duke University Medical Center, Durham,NC, (2)Duke University, Durham,NC Lay-language Version of WE-D-315-6 Wednesday, July 28, 2:45 PM 2004 AAPM Annual Meeting, Pittsburgh, PA Neutron Image of an Iron-Copper Sample INTRODUCTION In an active collaboration between the radiology and physics departments, Duke University researchers are developing a new approach to molecular imaging called Neutron Stimulated Emission Computed Tomography (NSECT). The long-term goal is to develop technology for non-invasively mapping the concentration of any isotope, stable or radioactive, in any selected 3-D volume of the body. ...

© The Ulster Medical Society, 2005. PET-CT in the diagnosis of recurrent rectal cancer 105 www.ums.ac.uk Ulster Med J 2005; 74 (2) 105-107 PET-CT in the diagnosis of recurrent rectal cancer complicated by left thigh abscess RT Skelly, CM McClintock, SJ Hughes, ST Irwin Accepted 30 June 2005 DepartmentofColorectalSurgery,TheRoyalVictoriaHospital, Belfast, Northern Ireland. RT Skelly, MD, FRCS(I), Specialist Registrar in Colorectal Surgery. C M McClintock, BSc, MB, BCh, Senior House Officer in Colorectal Surgery. ST Irwin, MD, DMI, FRCS, Consultant Colorectal Surgeon. Department of Nuclear Medicine. SJ Hughes, FRCR, Consultant in Radiology and Nuclear Medicine. Correspondenceto:Mr.Irwin,ConsultantColorectalSurgeon, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA. E-mail: terry.irwin@royalhospitals.n-i.nhs.uk ...

Reference Section a report by Er nest L Mazzaferri , MD , MACP President-Elect, American Thyroid Association (ATA) Types and Basic Biologic Features of Thyroid Cancer Differentiated Thyroid Cancer Thyroid cancer is the most common endocrine malignancy. It comprises several distinct tumor types; including papillary thyroid cancer (PTC); follicular thyroid cancer (FTC); and Hürthle cell thyroid cancer (HTC), which are tumors of the thyroid follicular cell derived from the embryonic foregut. They ordinarily concentrate iodine and sometimes synthesize and secrete thyroid hormone, and for this reason are collectively referred to as differentiated thyroid cancer (DTC).The three tumor types represent 80%, 11%, and 3% of all thyroid cancers, respectively, and have 10-year mortality rates of approximately ...

INCOGEN VIBE Mass Spectrometry (VIBE-MS) Software – Case Study Copyright 2005, INCOGEN, Inc., All Rights Reserved. Mass Spectrometry in Cancer Diagnosis A Case Study of the INCOGEN VIBE Workflow Software Background Recent advances in genomics and proteomics have greatly increased our understanding of the molecular basis for functions of organisms. However, the characterization of single genes or proteins has provided only limited insight and benefits toward early diagnoses, improved subtyping and prognoses, and treatment of diseases such as cancer . To understand the intricate web of interactions that makes up the biological functioning of life, we must try to decipher how a gene or protein fits into this dynamic environment with thousands of other genes and proteins. The interpretation of these dynamic systems is vastly more complex than, for example, sequencing the human genome, which is linear and, ...

Ultrasound Obstet Gynecol 2005; 26 : 558–566 Published online 8 August 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.1951 Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems Y.-L. HUANG*, S.-J. KUO†, C.-S. CHANG‡, Y.-K. LIU*, W. K. MOON§ and D.-R. CHEN† * Department of Computer Science and Information Engineering, Tunghai University, Taichung, Departments of † General Surgery and ‡ Medical Oncology, Changhua Christian Hospital, Changhua, Taiwan and § Department of Diagnostic Radiology, College of Medicine, Seoul National University Hospital, Seoul, South Korea KEYWORDS : breast cancer ; computer-aided diagnosis ; image retrieval; principal component analysis; textural analysis; ultrasound ABSTRACT Objectives We present a computer-aided diagnostic (CAD) system with textural features and ...

O varian cancer is the second most common gyneco- logic malignancy in the United States and, unfortunately, the most deadly. Ovarian cancer kills more women each year than all other gyneco- logic malignancies com- bined. This year it is esti- mated that approximately 24,000 new cases of ovari- an cancer will be diag- nosed and approximately 14,000 deaths will result from the disease. One of the reasons for the high fatal- ity rate is that more than 70% of women with ovarian cancer are diagnosed with advanced-stage disease. Five-year survival rates for women with disease in ad- vanced stages are only 20% to 30%; however, for those diagnosed when disease is confined to the ovary, cure rates are approximately 90%. 1 Although screening for ovarian cancer in the gener- al population is not yet feasible, it is important for women ...

Proceedings of International Joint Conference on Neural Networks, Montreal, Canada, July 31 - August 4, 2005 0-7803-9048-2/05/$20.00 ©2005 IEEE Ovarian Cancer Diagnosis Using Complementary Learning Fuzzy Neural Network T.Z. Tan, C. Quek, G.S. Ng Centre for Computational Intelligence (formerly known as Intelligent System Lab) School of Computer Engineering, Nanyang Technological University Blk N4, #B1a-02, Nanyang Avenue, Singapore 639798 Abstract —DNA microarray is an emerging technique in ovarian cancer diagnosis . However, very often, microarray data is ultra- huge and difficult to analyze. Thus, it is desirable to utilize Fuzzy Neural Network (FNN) approach for assisting the diagnosis and analysis process. Amongst FNN, complementary learning FNN is able to rapidly derive fuzzy sets and formulate fuzzy rules. Complementary learning FNN uses positive ...

2005 Special Issue Ovarian cancer diagnosis by hippocampus and neocortex-inspired learning memory structures T.Z. Tan, C. Quek, G.S. Ng* Centre for Computational Intelligence (formerly known as Intelligent System Lab), School of Computer Engineering, Nanyang Technological University, Blk N4, #B1a-02, Nanyang Avenue, Singapore 639798 Abstract Early detection and accurate staging of ovarian cancer are the keys to improving survival rate. However, at present there is no single diagnosis modality that is sufficiently sensitive. DNA microarray analysis is an emerging technique that has potential for ameliorating the hardship in early detection and staging of ovarian disease. However, microarray data is ultra-huge and difficult to analyze. Hence, computational intelligence methods are often utilized to assist in the diagnosis and analysis process. Fuzzy Neural Networks (FNN) are more suitable for this ...

a report by Philips Medical Systems With an estimated 2.9 million new cases per year, cancer remains an important public health problem in Europe. 1 The ageing European population will cause these numbers to continue to increase even if age-specific rates remain constant. The US faces the same epidemic with approximately 1,372,910 new cancer cases to be diagnosed in 2005. 2 These staggering statistics have lead to the advanced research and development of clinical techniques to more effectively diagnose and treat the disease. New applications and new techniques provide opportunities to diagnose patients sooner, treat patients faster and help patients experience a better quality of life. Early detection and early treatment of cancer patients in the US have resulted in increased survival rates from 50% in the 1970s to 74% today. 2 ...

Informatica 29 (2005) 61–70 1 Simulated Annealing Fuzzy Clustering in Cancer Diagnosis Xiao-Ying Wang, Jonathan M. Garibaldi Automated Scheduling, Optimisation and Planning (ASAP) Research Group Department of Computer Science & Information Technology The University of Nottingham, Jubilee Campus, Wollaton Road, United Kingdom {xyw, jmg}@cs.nott.ac.uk Keywords: Fourier Transform Infrared spectroscopy, Hierarchical Cluster Analysis, Fuzzy C-Means, Simulated Annealing Fuzzy Clustering, Xie-Beni validity measure. Received: 10 November 2004 Classification is an important research area in cancer diagnosis . Fuzzy C-means (FCM) is one of the most widely used fuzzy clustering algorithms in real world applications. However there are two major limitations that exist in this method. The first is that a predefined number of clusters must be given in advance. The second is that ...

A Robust Meta-Classification Strategy for Cancer Diagnosis from Gene Expression Data Gabriela Alexe IBM Computational Biology Center, IBM T.J. Watson Research, Yorktown Heights, NY 10598, USA galexe@us.ibm.com Ramakrishna Ramaswamy Center for Systems Biology, Institute for Advanced Study, Einstein Drive, Princeton NJ 08540, USA rama@ias.edu Gyan Bhanot IBM Computational Biology Center, IBM T.J. Watson Research, Yorktown Heights, NY 10598, USA, and Center for Systems Biology, Institute for Advanced Study, Einstein Drive, Princeton NJ 08540, USA gyan@us.ibm.com Jorge Lepre IBM Computational Biology Center, IBM T.J. Watson Research, Yorktown Heights, NY 10598, USA, leprej@us.ibm.com Gustavo Stolovitzky IBM Computational Biology Center, ...

C HAPTER 4: L UNG C ANCER D IAGNOSIS AND S TAGING INTRODUCTION The lungs are vital organs. Working with the heart and circulatory system, they provide life- sustaining oxygen and rid the body of carbon dioxide. Normal lungs have a great reserve capacity to meet the body’s need for oxygen across a wide variety of circumstances. The same is true of the heart and circulatory system. This reserve capacity permits cancerous lung tumors to grow for years without compromising lung function. Furthermore, the lungs do not have many nerves to transmit pain messages. Therefore, a cancerous lung tumor can grow for many years without causing any symptoms . Unfortunately, this means that most people are not diagnosed with lung cancer until late in the disease process. Even more unfortunate is the fact that this long period ...

Current Medical Imaging Reviews, 2006, 2, 000-000 1 1573-4056/06 $50.00+.00 ©2006 Bentham Science Publishers Ltd. Ultrasonic Elasticity Imaging as a Tool for Breast Cancer Diagnosis and Research Claire Pellot-Barakat 1,2 , Mallika Sridhar 1 , Karen K. Lindfors 3 , Michael F. Insana 1,4, * 1 Department of Biomedical Engineering, University of California, Davis CA, 2 INSERM UMR-S 678, Paris, France, 3 Radiology Department, University of California, Davis, Sacramento CA, 4 Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana IL Abstract: Ultrasonic elasticity imaging is a promising new tool for breast cancer diagnosis and management. Ultrasound is applied to sense small local tissue deformations noninvasively ...

271 V OLUME 3, N UMBER 4 ¦ J ULY /A UGUST 2005 www.SupportiveOncology.net Neuromuscular Complications of Cancer Diagnosis and Treatment Mohamed Falah,MD,David Schiff,MD,and Ted M.Burns,MD J Support Oncol 2005;3:271–282 © 2005 Elsevier Inc. All rights reserved. R E V I E W lopathies could also result from compression from epidural metastases. In such instances, myelopathy frequently accompanies any focal radiculopathy. In these cases, a magnetic resonance imaging (MRI) scan with gadolinium usually demonstrates leptomeningeal enhancement or compression of the nerve roots and cranial nerves by the tumor. Cerebrospinal fluid (CSF) analysis almost always reveals an elevated protein level and pleocytosis. 6 The CSF cytology demonstrates malignant cells ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN PANCREAS CANCER TISSUE MICROARRAY Catalog Number: TMA-007 Each core represents one specimen selected and pathologically confirmed. Normal matched or unmatched pancreatic tissue is provided for comparison to the cancer tissue. Cases : 70 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 D ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN ESOPHAGUS CANCER TISSUE MICROARRAY Catalog Number: TMA-014 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched esophageal tissue is provided for comparison to the cancer tissue. Cases : 40 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN THYROID CANCER TISSUE MICROARRAY Catalog Number: TMA-011 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched thyroid tissue is provided for comparison to the cancer tissue. Cases : 68 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Thyroglobulin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN SKIN CANCER TISSUE MICROARRAY Catalog Number: TMA-020 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched skin tissue is provided for comparison to the cancer tissue. Cases : 73 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 D ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN STOMACH CANCER TISSUE MICROARRAY Catalog Number: TMA-010 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched stomach tissue is provided for comparison to the cancer tissue. Cases : 40 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN COLON CANCER TISSUE MICROARRAY Catalog Number: TMA-004 Each core represents one specimen selected and pathologically confirmed. Normal matched or unmatched colon tissue is provided for comparison to the cancer tissue. Cases : 40 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 D 31 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN PROSTATE CANCER TISSUE MICROARRAY Catalog Number: TMA-008 Each core represents one specimen selected and pathologically confirmed. Normal matched or unmatched prostate tissue is provided for comparison to the cancer tissue. Cases : 78 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Anti-proliferating cell nuclear antigen confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN MULTIPLE TISSUE CANCER TISSUE MICROARRAY Catalog Number: TMA-009 Each core from each tissue represents one specimen selected and pathologically confirmed. Cases : 96 Cores : 96 Diameter : 1 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 10 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 D 31 32 33 34 35 36 37 38 39 40 ...

Time to Diagnosis and Treatment of Breast Cancer : Results from the National Breast and Cervical Cancer Early Detection Program 1991-1995 Lee S. Caplan, MD, MPH, PhD Daniel S. May, PhD, MPH Lisa C. Richardson, MD, MPH Division of Cancer Prevention and Control National Center for Chronic Disease Prevention and Health Promotion Page 2 Female Breast Cancer 179K cases in 1998 - most common malignancy 44K deaths in 1998 - 2nd leading cause of cancer death Little effective primary prevention available Secondary prevention is major means of control Screening reduces mortality by up to 30% BACKGROUND I Page 3 Early diagnosis and treatment associated with reduced breast cancer mortality ...

Automatic Cancer Diagnostic Automatic Cancer Diagnostic Decision Support System for Decision Support System for Gene Expression Domain Gene Expression Domain Alexander Statnikov Committee Members: • Dr. Constantin F. Aliferis (advisor) • Dr. Douglas P. Hardin • Dr. Shawn Levy • Dr. Ioannis Tsamardinos (advisor) Master’s Thesis Defense: Discovery Systems Laboratory, Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA 07/06/2005 Page 2 Problem Mapping of human genome Medicine Molecular Medicine Bioinformatics Molecular Biology An automated system for development and evaluation of high-quality cancer diagnostic models and biomarker discovery from microarray gene expression data prognosis ...

What my Illness Taught Me About Health (The Role of the Immunoglobulins) Allen R. Dyer, M.D., Ph.D. dyer@etsu.edu http://faculty.etsu.edu/dyer Page 2 Charles Janeway, M.D. Father of Clinical immunology • Pediatrician-in-chief at Boston Children’s Hospital for 30 years • Described “A gamma globulin emia” in children susceptible to infections Page 3 Patient: ARD • Aug, 1997 - First symptoms: chin numbness • Jan, 1998 - Rib tenderness • March, 1998 - diagnosis : Multiple Myeloma • March - June: 3 rounds of low-dose chemo • July-Sept: Bone Marrow Transplant Page 4 Differential Diagnosis of Chin numbness/pain • Multiple sclerosis • Brain tumor • Trigeminal neuralgia • Herpes ...

For more information about breast health or breast cancer , call the Susan G. Komen Breast Cancer Foundation’s Toll-Free Helpline at 1.800 I’M AWARE ® (1.800.462.9273) or visit the Web site at www.komen.org. coping with a cancer diagnosis Feel like you are losing control? When told they have breast cancer , many women feel they have lost control of their lives. Still others feel overwhelmed by all the decisions they have to make. These feelings are normal, but do not let them keep you from taking action. First, learn about breast cancer . Get information about clinical trials, treatment options and side effects. Remember, doctors can make recommendations, but decisions must be made by you and your doctor. Knowing what to expect is another key to staying in control. It may also help to keep as normal a routine as possible. However, be patient with yourself. ...

For more information about breast health or breast cancer , call the Susan G. Komen Breast Cancer Foundation’s Toll-Free Helpline at 1.800 I’M AWARE ® (1.800.462.9273) or visit the Web site at www.komen.org. Anyone who has ever had cancer remembers what it felt like hearing the diagnosis for the first time. You can feel angry, afraid, cheated, overwhelmed and uncertain about the future. But in time you learn you can take control of your life. Your medical team, family and friends (your co-survivors) can help you through the process. Here’s how: STEP 1: Planning your journey Your doctor reviewed your pathology report and made a diagnosis of breast cancer . The same report will be used to determine your prognosis (chances of recovery from breast cancer ) and to suggest a course of treatment. Making this plan is the first step in the process of healing. You can ...